Associated Papers
Malignant adenomyoepithelioma with HRAS G13R mutation: A case report.
Kuwabara H et al.
Oncology Letters, 2026
Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer.
Ochman B et al.
International Journal of Molecular Sciences, 2026
Six-Color Multiplex Digital PCR Assays for Comprehensive Screening and Identification of Multiple Driver Mutations Associated with Pancreatic Carcinogenesis.
Maeda C et al.
Clinical Chemistry, 2026
RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.
Baars B et al.
Molecular Cancer Research : Mcr, 2026
Prognostic Significance of SOX9 and Its Combination With RAS and TP53 Mutations Following Colorectal Cancer Liver Metastasectomy.
Duan JL et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2025
Isolated KRAS and NRAS mutations in adults with monocytosis and/or cytopenia(s).
Wang SA et al.
Haematologica, 2025
A hyperactive splice variant of STAT3 promotes colonic inflammation-associated tumorigenesis in mice.
Xu M et al.
Science Translational Medicine, 2025
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Harnessing liquid biopsy to unveil RAS-MEK pathway somatic pathogenic variants in extracranial arterio-venous malformations.
Bhatia KD et al.
Communications Medicine, 2025
Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing: An International Multicenter Study.
Lescuyer G et al.
The Journal of Molecular Diagnostics : Jmd, 2025
KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials.
Navarro-Jiménez M et al.
Npj Precision Oncology, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.
Hamza A et al.
British Journal of Cancer, 2025
Functional Analysis of Rare RAS Variants of Unknown Significance.
Park S et al.
Cancer Research Communications, 2025
Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.
Kavgaci G et al.
Molecular Oncology, 2025
The Impact of RAS/BRAF Mutation on Pathological Complete Response After Total Neoadjuvant Therapy in Rectal Cancer.
Aboelmaaty S et al.
Annals of Surgical Oncology, 2025
Problems in Cancer Genome Medicine: Base Mutations Cause Intron Start Signals, Resulting in Unexpected Splicing.
Hayashi T et al.
World Journal of Oncology, 2025
U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations.
Walter DM et al.
Biorxiv : the Preprint Server for Biology, 2025
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?
William D et al.
Esmo Gastrointestinal Oncology, 2025
MRD4U: A path to development for personalized liquid biopsy for children with central nervous system tumors.
Miller AR et al.
Bmc Cancer, 2025
Clinical and prognostic characteristics of metastatic colorectal cancer with minor RAS mutations.
Kojitani Y et al.
Oncology Letters, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Janku F et al.
Jco Precision Oncology, 2025
Denitrogenative Alkylation of K-Ras(G12D) Inhibits Oncogenic Signaling in Cancer Cells.
Zheng Q et al.
Journal of the American Chemical Society, 2025
Evaluation of Bridge Capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients.
Ganesan A et al.
Scientific Reports, 2025
Clonal Hematopoiesis of Indeterminate Potential Is Associated With Incident Abdominal Aortic Aneurysm.
Tan Y et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2025
Clinicopathologic characteristics, co-mutation landscape, and survival outcomes of KRAS-G12D mutant lung adenocarcinoma in comparison to KRAS-G12C and EGFR-mutated subtypes.
Abolfathi H et al.
Lung Cancer (amsterdam, Netherlands), 2025
Site-Specific Mutations on KRAS, NRAS, and BRAF Corelate With the Frequency of ctDNA in Colorectal Cancer.
Yoshimura F et al.
Cancer Reports (hoboken, N.j.), 2025
Prostate Ductal Adenocarcinoma Revisited: Clinicopathological and Genomic Characterization Identifies Heterogenous Group of Diseases with Implications for Patient Management.
Cai Q et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
UNISOM: Unified Somatic Calling and Machine Learning-based Classification Enhance the Discovery of CHIP.
Tian S et al.
Genomics, Proteomics & Bioinformatics, 2025
Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients.
van der Leest P et al.
Communications Medicine, 2025
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras.
Parry CW et al.
Journal of Medicinal Chemistry, 2025
Targeting Hyperactive Ras Signaling in Pediatric Cancer.
Levinson A et al.
Cold Spring Harbor Perspectives in Medicine, 2025
Performance and considerations in the use of diagnostic mutation panels for clonality testing in non-small-cell lung carcinoma.
Janssen J et al.
Esmo Open, 2025
The Role of RAS in CNS Tumors: A Key Player or an Overlooked Oncogene?
de Souza Barbosa I et al.
International Journal of Molecular Sciences, 2025
Prevalence and breakdown of KRAS driver mutations in a large UK non-small cell lung cancer cohort.
Niesner ICC et al.
Journal of Clinical Pathology, 2025
The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer.
Farooq AR et al.
Npj Precision Oncology, 2025
Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes.
Iranmanesh Y et al.
The Oncologist, 2025
The diagnostic value of comprehensive next-generation sequencing for genetic mutations in suspected lung cancer cases with negative pathological cytology.
Goto Y et al.
Lung Cancer (amsterdam, Netherlands), 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition.
Zhang T et al.
Biorxiv : the Preprint Server for Biology, 2025
Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients.
Riner AN et al.
Pancreas, 2025
Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers.
Xia RX et al.
Acta Pharmacologica Sinica, 2025
Prognosis conferred by molecular features of appendix-derived Pseudomyxoma Peritonei.
Ma R et al.
Translational Oncology, 2025
Molecular Profiling of Low-Risk Papillary Thyroid Carcinoma (mPTC) on Active Surveillance.
Ramone T et al.
The Journal of Clinical Endocrinology and Metabolism, 2025
Role of silent mutations in KRAS -mutant tumors.
Lu J et al.
Chinese Medical Journal, 2025
Investigating the Pathogenicity of Uncommon KRAS Mutations and Their Association with Clinicopathologic Characteristics in Patients with Colorectal Cancer.
Adorisio R et al.
The Journal of Molecular Diagnostics : Jmd, 2025